Legofer (Iron Protein Succinylate)

Legofer is an oral iron supplement that addresses disorders of iron metabolism and related anemia.

• Iron deficiency anemia: restores normal hemoglobin and ferritin levels, alleviating fatigue and weakness.
• Anemia of chronic kidney disease: supports erythropoiesis when endogenous iron stores are insufficient.
• Post‑surgical blood loss anemia: replenishes iron lost during operative procedures to promote recovery.

• Iron Protein Succinylate dissociates in the gastrointestinal tract, releasing elemental iron that is absorbed via the duodenal divalent metal transporter (DMT1). The absorbed iron enters the plasma pool, where it is incorporated into hemoglobin within erythroblasts and utilized by iron‑dependent enzymes, supporting oxygen transport and cellular metabolism.

Legofer may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Constipation: reduced bowel movements.
• Abdominal discomfort: cramping or pain.
• Darkened stools: harmless change in stool color.
• Metallic taste: transient alteration in taste perception.
• Diarrhea: loose stools in some individuals.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Iron overload: excessive iron accumulation with long‑term misuse.
• Significant gastrointestinal bleeding: rare but potentially serious.
• Hypotension: low blood pressure after rapid absorption.
• Hemolysis: destruction of red blood cells in susceptible patients.
• Acute iron toxicity: occurs with accidental overdose.

Before initiating therapy with Legofer, several safety considerations should be observed.

• Assess iron status: confirm deficiency with laboratory tests before prescribing.
• Monitor hemoglobin: periodic checks to evaluate response and avoid excess.
• Hypersensitivity: discontinue if signs of allergic reaction appear.
• Gastrointestinal disorders: use cautiously in patients with IBD or ulcer disease.
• Pregnancy and lactation: evaluate risk‑benefit ratio; consult obstetric guidance.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Legofer can affect the absorption or efficacy of several concomitant medicines.

Major Interactions (Avoid)

• Tetracycline antibiotics: chelation reduces absorption of both agents.
• Levothyroxine: iron interferes with thyroid hormone uptake.
• Bisphosphonates: concurrent intake diminishes oral bioavailability.
• Quinolone antibiotics: reduced antimicrobial effectiveness.
• Calcium supplements: competitive inhibition of iron absorption.

Moderate Interactions (Monitor Closely)

• Proton pump inhibitors: decreased gastric acidity may lower iron uptake.
• Antacids containing magnesium or aluminum: can bind iron and limit absorption.
• Foods high in phytates (e.g., legumes, whole grains): may reduce iron bioavailability.
• Oral contraceptives: monitor for altered iron parameters.
• Certain diuretics (e.g., thiazides): watch for electrolyte shifts when combined with iron therapy.